Colorectal Cancer Follow-up Care Pathway Map

Version 2018.03

The cancer journey
Better cancer services every step of the way

Disclaimer
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.
Target Population
Colorectal cancer survivors: adult patients who have completed primary treatment and are without evidence of disease, but would potentially be candidates for further treatment if recurrence were detected.

Pathway Map Considerations
- Primary care providers play an important role in the cancer journey and should be informed of relevant tests and consultations. Ongoing care with a primary care provider is assumed to be part of the pathway map. For patients who do not have a primary care provider, Health Care Connect, is a government resource that helps patients find a doctor or nurse practitioner.
- Throughout the pathway map, a shared decision-making model should be implemented to enable and encourage patients to play an active role in the management of their care. For more information see Person-Centered Care Guideline.
- Hyperlinks are used throughout the pathway map to provide information about relevant CCO tools, resources and guidance documents.
- The term 'health care provider', used throughout the pathway map, includes primary care providers and specialists, nurse practitioners, and emergency physicians.
- The pathway map is only intended for primary adenocarcinomas. Familial cancers (Lynch/non-Lynch) and cancers in the settings of inflammatory bowel disease are handled differently.

Pathway Map Disclaimer
This pathway map is a resource that provides an overview of the treatment that an individual in the Ontario cancer system may receive.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

While care has been taken in the preparation of the information contained in the pathway map, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability. CCO and the pathway map’s content providers (including the physicians who contributed to the information in the pathway map) shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the pathway map or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the pathway map does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the pathway map.

This pathway map may not reflect all the available scientific research and is not intended as an exhaustive resource. CCO and its content providers assume no responsibility for omissions or incomplete information in this pathway map. It is possible that other relevant scientific findings may have been reported since completion of this pathway map. This pathway map may be superseded by an updated pathway map on the same topic.
Procedures and Protocols

**Colonoscopy**
- 1 year after initial surgery OR within 6 months of completing surgery if a complete colonoscopy was not performed pre-operatively
- Frequency of subsequent surveillance colonoscopies should be based on the findings of the previous one
- Generally, every 5 years, if the previous findings are normal

**CT Chest**
- Annually for 3 years
- or alternatively
  - **X-ray Chest**
  - **Ultrasound Abdomen**
  - **Ultrasound Pelvis** (if previously treated for rectal cancer)

**CT Abdomen**
- Every 6 months for 5 years

**CT Pelvis** (if previously treated for rectal cancer)
- Every 6 – 12 months for 3 years, then annually for year 4 and 5

**Quality Management Program for Colonoscopy**

Guideline #19-5

Guideline #19-4

**Preventing Colon Cancer**

**Medical History & physical exam**
- To include symptoms related to bowel, bladder and colostomy management

**Carcinogenic Embryonic Antigen (CEA)**
- Any abnormal result suspicious for recurrence and/or metastatic disease

**Screen for psychosocial needs, and assessment and management of symptoms.**

**Consider the introduction of palliative care, early and across the cancer journey.**

1. There is limited evidence for the surveillance of patients treated for stage I and stage IV colorectal cancer. The surveillance protocol of these patients should be individualized based on tumour stage and patient characteristics.

2. For patients that present with symptoms concerning for recurrence, investigations should be performed and a referral back to the appropriate specialist should be considered.

3. For rectal cancer patients who are considered at high risk of local recurrence by the treating physician, sigmoidoscopy can be considered at intervals less than 5 years.

4. The choice of Chest CT or Chest X-ray should be consistent with the modality used for preoperative staging. For more information, refer to EBS #17-8.
Colorectal Cancer Follow-up Care Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Suspicions of Recurrent Disease

Abnormal Colonoscopy (i.e., suspicious for a new primary tumour or local recurrence)

Abnormal Abdominal/Pelvic Imaging (i.e., suspicious for liver metastases)

Abnormal Chest Imaging (i.e., suspicious for lung metastases)

Elevated Carcinogenic Embryonic Antigen (CEA)

Results

Isolated Local Rectal Recurrence

Isolated Metastases

Local Rectal Recurrence with Metastases

New Primary Colon or Rectal Tumour with or without Metastases

Other Malignancy

Elevated CEA only

Individualized Investigations & Management

PET Scans Ontario

PET Scans Ontario

Results

No evidence of disease

Follow-up with Specialist as appropriate

Evidence of disease

Proceed to Colon or Rectal Cancer Treatment Pathway Map (Page 5 & 7, respectively)

Proceed to Rectal Cancer Treatment Pathway Map (Page 6)

Proceed to Rectal Cancer Treatment Pathway Map (Page 5 – treat as prescribed but for local recurrence)

Proceed to Stage-Appropriate Colon or Rectal Cancer Treatment Pathway Map

Refer to Appropriate Specialist

Additional work-up to complete restaging

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey Click here for more information about palliative care

From Page 3

Oncology Team

PET Scans Ontario

* Patients with an elevated CEA but no other evidence of disease should be followed at the discretion of the treating physician. Tumour markers have some variability and are not confirmatory for local recurrence and/or metastatic disease.

* Refer back to one of the original treating physicians as appropriate and available.